Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference
-
Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
-
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
-
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
-
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Sloane & Company, a strategic communications firm at the intersection of valuation and reputation, announces the appointment of Leslie Wheeler as a...
-
Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
-
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting